Abstract Although widespread resistance of Leishmania donovani and L. infantum against miltefosine (MIL) and paromomycin (PMM) has not yet been demonstrated, both run the risk of resistance selection. Unraveling the dynamics and mechanisms of resistance development is key to preserve drug efficacy in the field. In this study, resistance against PMM and MIL was experimentally selected in vitro in intracellular amastigotes of several strains of both species with different antimony susceptibility background. To monitor amastigote susceptibility, microscopic determination of IC 50 -values and promastigote back-transformation assays were performed. Both techniques were also used to evaluate the susceptibility of field isolates from MIL-relapse patients. PMM-resistance could readily be selected in all species/strains, although promastigotes remained fully PMM-susceptible. Successful MIL-resistance selection was demonstrated only by promastigote back-transformation at increasing MIL-concentrations upon successive selection cycles. Important to note is that amastigotes with the MIL-resistant phenotype could not be visualized after Giemsa staining; hence, MIL-IC 50 -values showed no shift. The same phenomenon was observed in a set of recent clinical isolates from MIL-relapse patients. This study clearly endorses the need to use intracellular amastigotes for PMM-and MIL-susceptibility testing. When monitoring MILresistance, promastigote back-transformation should be used instead of the standard Giemsa staining. In-depth exploration of the mechanistic background of this finding is warranted.
Introduction
Visceral leishmaniasis (VL) is caused by Leishmania donovani or Leishmania infantum and may be fatal if left untreated. Current treatment options are limited with few novel drugs in the pipeline. Pentavalent antimonials (Sb V ) have long been used as first-line therapy despite several major drawbacks, such as the need for parenteral administration and potentially severe toxic side effects (Frezard et al. 2009 ). The emerging Sb V drug resistance further compromises current VL treatment, especially in the Indian subcontinent (Sundar 2001) . In this high endemic region, miltefosine (MIL) and paromomycin (PMM) were recently introduced as first-line alternatives for Sb V therapy (Sundar et al. 2002; ). Clinical studies confirmed the efficacy and tolerability of both, either as monotherapy or in combination with other antileishmanial drugs (Davidson et al. 2009; van Griensven et al. 2010) . While development of resistance towards aminoglycosides such as PMM is frequently encountered in a variety of bacteria (MingeotLeclercq et al. 1999) , MIL requires a long treatment regimen and has a long elimination half-life (Sundar and Olliaro 2007) . Once routinely used in the field, PMM and MIL are thus at considerable risk for the development of drug resistance.
To safeguard the efficacy of the few available drugs, the dynamics and molecular mechanisms of resistance should be studied proactively. Since resistance against PMM or MIL has not yet been widely observed in the field, laboratory studies still rely on the experimental selection of PMM-and MIL-resistance (Chappuis et al. 2007) . Until now, resistance was generally selected on promastigotes which can be easily cultivated in vitro and exposed to increasing drug concentrations (Maarouf et al. 1998; Seifert et al. 2003) . However, this "insect" stage is a priori the less appropriate stage to measure resistance, as it is the intracellular amastigote that is exposed to drugs in patients. Furthermore, resistance selected in one stage may not necessarily translate to another stage. Indeed, our group recently reported a novel resistance selection protocol for drug pressure on the intracellular amastigote stage, resulting in a PMMresistant L. donovani strain with amastigotes tolerating four times higher PMM-concentrations, while the promastigotes remained fully PMM-susceptible (Hendrickx et al. 2012) .
To expand to other VL species and to include the effect of the Sb V resistance background on the development of PMMresistance, the present study used a set of L. donovani and L. infantum strains with different Sb-susceptibility background. In addition, the resistance selection protocol on intracellular amastigotes was also used for the selection of MILresistance on the same set of Leishmania strains. To clinically validate the experimental data, the susceptibility of a small number of field isolates of MIL-relapse patients was assessed.
Materials and methods
Strain selection and parasite cultivation L. donovani clinical isolates were used for resistance selection (MHOM/NP/03/BPK275/0 cl18, Sb V resistant; MHOM/NP/ 03/BPK 206/0 cl10 and MHOM/NP/02/ BPK 282/0 cl4, both Sb V sensitive). The Institute of Tropical Medicine (Antwerp, Belgium) provided the strains within the framework of the EU-Kaladrug-R project (http://www.leishrisk.net/kaladrug). The parent strains were isolated from bone marrow aspirates of patients in the Terai endemic region in Nepal (BP Koirala institute, Dharan, Nepal). The strains were typed as L. donovani by CPB-PCR-RFLP and their full genome sequences are available (Downing et al. 2011; Quispe Tintaya et al. 2004 ). et al. 2011) . Species identification of the L. infantum strains was done using isoenzyme electrophoresis and pteridinereductase 1 (PTR1) sequencing. Promastigotes of all strains were cultured in HOMEM promastigote medium (Gibco®, Life technologies, Ghent, Belgium) supplemented with 10 % inactivated fetal calf serum (iFCS).
Resistance selection protocol
The method developed by Hendrickx et al. (2012) (Fig. 1 ) was used to select for drug resistance on intracellular amastigotes. In brief, primary peritoneal macrophages (mφ) were collected from starch-stimulated female Swiss mice and seeded into duplicate 96-well plates in RPMI-1640 culture medium (Gibco®, Life technologies). Two days later, mφ were infected with stationary-phase promastigotes at a ratio of 1:15. One day postinfection, non-internalized promastigotes were removed by repetitive (n≥3) washing cycles with PBS. Next, intracellular amastigotes were exposed to twofold drug dilution series starting from the cytotoxic thresholds, i.e. 500 μM for PMM and 40 μM for MIL. After 4 days of drug pressure, one plate was Giemsa-stained to assess amastigote susceptibility, while the duplicate plate was used for promastigote back-transformation. Promastigotes were harvested from the highest concentration with visible promastigote growth, brought into culture, and used to infect macrophages for the next selection round. Successive rounds of drug exposure and promastigotes expansion were repeated until cutoff values for drug resistance were reached, i.e. 150 μM for PMM and 15 μM for MIL according to published and experimental susceptibility data ).
Amastigote susceptibility assay
To determine PMM-and MIL-IC 50 -values of intracellular amastigotes, amastigote burdens were compared between treated mφ and untreated control cells. Mφ were fixed with methanol and Giemsa-stained for microscopic determination of the number of amastigotes per cell. Susceptibility assays always included Sb V (Calbiochem®, EMD Millipore Corporation, Billerica, USA), Sb III , PMM and MIL (SigmaAldrich, Diegem, Belgium) and were run in triplicate.
Promastigote back-transformation
Mφ were mechanically disrupted to release the remaining amastigotes in HOMEM promastigote medium. At 25°C, amastigotes readily transform back into promastigotes and start replication.
Promastigote susceptibility assay
To determine susceptibility of recovered promastigotes, IC 50 -values of treated and untreated parasites were compared as described previously (Inocencio da ). After exposure of log-phase promastigotes to twofold drug dilutions for 72 h, resazurin was added for fluorimetric determination of promastigote viability (Tecan®, GENios). As for the amastigote susceptibility assay, Sb V , Sb III , PMM, and MIL were included and were run in triplicate.
Determination of MIL susceptibility of field isolates
To assess the clinical significance of the experimental resistance data, a limited set of L. donovani pretreatment and MILrelapse isolates (MHOM/NP/09/BPK455/0 cl2, MHOM/NP/ 09/BPK455/2 cl3, MHOM/NP/10/BPK471/10 and MHOM/NP/10/BPK520/0; Table 3 ) was subjected to amastigote susceptibility testing, based on standard microscopic reading after Giemsa staining as well as on promastigote back-transformation complemented with promastigote susceptibility testing.
Results

PMM resistance selection
The results of the PMM-resistance selection on amastigotes of different L. donovani and L. infantum strains are presented in Table 1 . All strains reached the PMM-resistance cutoff value of 150 μM after two or three selection cycles (Fig. 2) , regardless of their Sb-susceptibility background. In contrast, no major changes could be detected in the PMM-sensitivity of , or MIL susceptibility profile remained unaltered. Strain BPK282/0 cl4 proved to be naturally resistant to PMM (IC 50 =263.2±54.5 μM), which had already been established in frame of the Kaladrug-R project, and was therefore not subjected again to PMM-resistance selection cycles.
MIL-resistance selection
Positive promastigote back-transformations at increasing MIL-concentrations upon repeated drug exposure demonstrated successful MIL-resistance selection (Table 2, Fig. 2 ). With successive selection cycles, the concentrations at which promastigotes could be harvested gradually increased. For example, back-transformation of BPK 206/0 Cl10 was only positive up to 5 μM after one selection round, while promastigotes could be harvested up to 10 μM after the second selection cycle and up to 20 μM after the third selection cycle. After back-transformation and expansion, the selected promastigotes showed a MIL-susceptible phenotype.
Gradual MIL-resistance selection did not induce a shift of IC 50 -values in the standard amastigote susceptibility tests since amastigotes with MIL-resistant phenotype could not be visualized and microscopically quantified after Giemsa staining. The original Sb V -, Sb III -, or PMM-susceptibility profile remained unaltered. LEM5159 displayed primary MILresistance on both promastigote and amastigote level and was therefore not subjected to additional MIL-selection pressure.
MIL-susceptibility of clinical isolates
Promastigote susceptibility testing and intracellular amastigote counting after Giemsa staining suggested that all isolates were MIL-susceptible (IC 50 -values <5 μM) (Table 3) . Promastigote back-transformation, however, shed a new light on the susceptibility profile of several isolates. Promastigotes of BPK520/0 could be harvested from cells treated with up to 10 μM, indicating MIL-susceptibility. For BPK455/0 cl2 and BPK455/2 cl3, the promastigote back-transformation assay was positive in wells treated with 20 μM for both strains. Compared to BPK275/0 cl18, BPK282/0 cl4, and BPK206/ 0 cl10 (Table 1) , BPK455/0 cl2 showed a higher intrinsic MILtolerability on amastigote level. BPK471/7 promastigotes could be harvested from cells exposed to 40 μM, i.e., the mφ cytotoxic concentration, which corresponds with MILtolerability.
Discussion
In the last decade, the emergence of resistance against antimonials has severely compromised their value as first-line VL therapy. Nowadays, up to 65 % of the infected patients in some districts of Bihar (India) no longer responds to Sb PMM is characterized by a good efficacy, low cost, short administration time, and excellent safety profile, while MIL is the only oral VL therapy and is associated with low cost and only moderate side effects (Davidson et al. 2009 ). Therefore, it was introduced in 2005 in India as part of the Kala-Azar Elimination program that aims to reduce the number of VL IC 50 -values of promastigotes and intracellular amastigotes are shown (standard susceptibility assays) and the concentration at which back-transformation to promastigotes occurred (single replicate testing) SEM standard error of the mean cases to less than 1/10,000 by 2015 (Dhillon et al. 2008 ). However, its long elimination half-life and long treatment regimen (Dorlo et al. 2012) place the drug at high risk for resistance development. Currently, an increasing number of VL patients in the Indian subcontinent has already shown MIL-treatment failure, although widespread field resistance, i.e., a decreased in vitro MIL-susceptibility, has not yet been demonstrated in the corresponding L. donovani isolates (Rijal et al. 2013; Sundar et al. 2008; Sundar et al. 2012; Sundar and Olliaro 2007) . In post-kala-azar dermal leishmaniasis, two L. donovani clinical isolates from MIL-relapse patients showed an IC 50 , as measured by intracellular amastigote counting after Giemsa staining (Kulshrestha et al. 2013) , above the 15 μM-threshold indicating MIL-resistance. For L. infantum, one MIL-resistant isolate from a HIV-infected VL patient from France was recently documented (Cojean et al. 2012 ). The present paper reports the existence of a second MIL-resistant isolate from a French HIV-positive VL patient (Table 1 : strain LEM5159) which had been treated with various courses of MIL and amphotericin-B (personal communication L. Lachaud).
To tackle the clinically important issue of PMM-and MILresistance development and to gain better insight into the dynamic mechanisms involved, in-depth research on resistant Leishmania is required. Since PMM-or MIL-resistant field isolates are yet not commonly available, experimentally selected resistant strains provide a starting point for geno-and phenotypical analyses (Jeddi et al. 2011) .
It has already been shown that PMM-and MIL-resistance can be readily induced on promastigotes, even in combination therapy (Garcia-Hernandez et al. 2012; Maarouf et al. 1998; Seifert et al. 2003) . However, only intracellular amastigotes are exposed to drug selection pressure in the host and potentially adapt to increasing drug concentrations ). To mimic the development of resistance in the field more closely, our group developed a novel in vitro resistance selection protocol on amastigote level (Hendrickx et al. 2012) . This approach proved to be reproducible and reliable for the selection of PMM-resistance in the current set of L. donovani and L. infantum strains. PMM-resistance was achieved on amastigote level in all selected strains after maximum three successive selection cycles regardless of the Sb V / Sb III -susceptibility background (Table 1 ). An important observation was that finally all back-transformed promastigotes maintained their original PMM-susceptibility. In contrast, previous studies indicated that PMM-resistance selection on promastigotes leads to a decreased sensitivity on promastigote and amastigote level (Kulshrestha et al. 2013; Maarouf et al. 1998) , clearly demonstrating that the outcome of selection on promastigotes or amastigotes does not necessarily correlate. Overall, our findings have important consequences for the epidemiological monitoring of PMM-resistance, as the standard approach of promastigote susceptibility testing in the field may not reveal the resistant phenotype of the amastigote. Hence, we strongly recommend the use of amastigote susceptibility testing to assess PMM-resistance in the field, even though this requires a more complex laboratory setup ) that may not be readily available in poor endemic regions.
Upon MIL-selection on amastigotes, all isolates showed quite unexpected results. IC 50 -values based on microscopic counting of Giemsa-stained intracellular amastigotes remained stable upon successive MIL-pressure cycles. However, after repeated drug exposure, promastigotes could be harvested at gradually increasing MIL-concentrations in promastigote back-transformation assays, indicating selection of parasites towards a MIL-resistant phenotype. Apparently, this parasite form cannot be detected by light microscopy after Giemsa staining. To evaluate the clinical relevance of this finding, we evaluated the susceptibility of different Nepalese isolates using the promastigote back-transformation assay in relation to their MIL-treatment response in a small pilot study (Table 3 ). In this limited set of samples, the treatment outcome and the promastigote back-transformation assay showed a good correlation. During back-transformation, BPK520/0 promastigotes could be harvested from cells treated with up to 10 μM MIL. This MIL-susceptibility is in accordance with the positive clinical outcome of MIL-treatment. BPK471/7 promastigotes could be harvested from cells exposed to 40 μM, i.e., the mφ cytotoxic concentration, which corresponds with MIL-resistance in the relapse patient. For BPK455, the promastigote back-transformation assay was positive in wells treated with 20 μM for both the pre-and posttreatment isolate, suggesting that in this particular patient, MIL-tolerant parasites were already present before the onset of the treatment. Microscopic counting of intracellular amastigote burdens did not indicate MIL-resistance in this isolate, which corresponds with our experimental in vitro selection results. The evolution of the MIL-susceptibility during treatment and the correlation of the back-transformation and treatment outcome should be more extensively studied in coupled isolates of treated patients, which are unfortunately scarcely available. Although promastigote susceptibility testing has often been considered adequate for routine MILsusceptibility monitoring (Kulshrestha et al. 2013) , our results suggest that the intracellular amastigote assay combined with promastigote back-transformation should be used. Swift implementation of the proposed promastigote backtransformation assay may entail some practical problems, such as the difficulty to adapt clinical isolates to in vitro culture leading to insufficient infection of macrophages. Fundamental research is ongoing to explain why the resistant phenotype is not maintained upon promastigote backtransformation and how promastigotes can originate from cells in which no amastigotes can be visualized by standard Giemsa staining.
